Radiopharm initiated with a Buy at ThinkEquity

ThinkEquity initiated coverage of Radiopharm (RADX) with a Buy rating and $15 price target Radiopharm is a dual-listed, clinical-stage radiopharmaceutical company developing a diversified pipeline of diagnostic and therapeutic agents for solid tumors, the analyst tells investors in a research note. The firm says the company’s clinical and preclinical programs are grounded in molecular targets with established biological validation but limited radiopharmaceutical competition.